Company Overview and News


Add CELGZ
to your dashboard

Headline News

Your Daily Pharma Scoop: Exelixis Still Attractive, Portola's BevyxXa, Pluristem Patent

21h seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (251-1)

The 7 Best Growth Funds to Beat the Market in 2018

2017-11-22 investorplace
The fundamental performance goal for most investors is to outperform the S&P 500 Index, and a smart way to do this is with the best growth funds. As the common investment disclaimer reminds us, past performance is no guarantee of future results. But there’s also truth in the famous Mark Twain quote: “History doesn’t repeat itself but it often rhymes.” (548-3)

J&J Seeks Darzalex's Label Expansion in First-Line Setting

2017-11-22 zacks
Johnson & Johnson (JNJ - Free Report) announced the submission of regulatory applications to the FDA and the European Medicines Agency ("EMA") seeking label expansion of its multiple myeloma (“MM”) drug Darzalex in the first-line setting. (190-0)

UPDATE 1-J&J multiple myeloma drug succeeds in first-line combination study

2017-11-21 reuters
(Reuters) - Johnson & Johnson’s blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday. (56-0)

J&J multiple myeloma drug succeeds in first-line combination study

2017-11-21 in.reuters
(Reuters) - Johnson & Johnson’s blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with the standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday. (56-0)

Celgene Corporation Stock Is a Steal Right Now, Here’s Why

2017-11-21 investorplace
A number of biotech firms that have real long-term growth have for some reason, cheaper share prices than you’d expect, and Celgene Corporation (NASDAQ:CELG) could be one of the biggest bargains of all. (56-0)

Celgene (CELG) a Sell on Flagging Quant Score

2017-11-21 investorplace
The current recommendation of Sell for Celgene Corp (NASDAQ:CELG) has been derived by using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for the last month. (56-0)

Cancer Space Update: Label Expansion for Three Major Drugs

2017-11-17 zacks
With a busy earnings season almost coming to an end after an impressive run, we are again focused on latest cancer updates happening every week. The week gone by saw three cancer drugs receiving FDA approval for new indications – Roche Holding AG’s (RHHBY - Free Report) Gazyva, Pfizer Inc.’s (PFE - Free Report) Sutent and AstraZeneca PLC’s (AZN - Free Report) Faslodex. However, an interesting product in development is a cancer vaccine that Moderna Therapeutics and Merck (MRK - Free Report) are working on. (396-1)

CELG Stock: Celgene Corporation Attempts a Breakout | InvestorPlace

2017-11-17 investorplace
Shares of large-cap biotechnology stocks as a group and as represented by the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) rallied on Thursday  as a broader risk-on feel came back to the world of U.S. equities. Among this group, beaten down Celgene Corporation (NASDAQ:CELG) for the first time in more than two months flashed a better-quality trading buy signal. (56-0)

BRIEF-Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA

2017-11-16 reuters
* Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma (56-0)

Look At Deutsche International Growth A Fund (SGQAX)

2017-11-16 zacks
Deutsche International Growth A Fund (SGQAX - Free Report) seeks long-term appreciation of capital. SGQAX normally invests in the securities of non-U.S. issuers across the globe, with any market capitalization. SGQAX invests in preferred stocks, convertible securities and warrants. SGQAX also invests about one-fifth of its assets in securities of domestic issuers. (57-0)

Astellas faces U.S. probe over patient assistance charity support

2017-11-15 reuters
BOSTON (Reuters) - Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers’ financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. (259-0)

Astellas faces US probe over patient assistance charity support

2017-11-15 channelnewsasia
Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. (259-0)

Focus on Deutsche International Growth S Fund (SCOBX)

2017-11-15 zacks
Deutsche International Growth S Fund (SCOBX - Free Report) seeks long-term appreciation of capital. SCOBX normally invests in the securities of non-U.S. issuers across the globe, with any market capitalization. SCOBX invests in preferred stocks, convertible securities and warrants. SCOBX also invests about one-fifth of its assets in securities of domestic issuers. (74-0)

Top 4 Inexpensive Healthcare Mutual Funds for 2018

2017-11-14 zacks
The overall demand for new innovative medical products and services has continued to rise due to an ageing population.  This increase in demand for new drugs, therapies, and medical instruments is expected to be a long term growth driver for the Healthcare sector.  Innovations by medical devices companies, drug makers, and improvements in new technology have been the driving force behind the Healthcare sector over the past several quarters. (220-0)

CUSIP: 151020112